Markets

Insider Trading

Hedge Funds

Retirement

Opinion

14 Biotech Stocks with High Potential

Page 1 of 13

In this article, we will look at the top 14 Biotech Stocks with High Potential.

On October 1, Evan Seigerman, head of healthcare research at BMO Capital Markets, appeared on CNBC’s “The Exchange” to talk about what the future may be like for healthcare stocks.

Healthcare was the second worst performer this year, with pharma and biotech companies under pressure. However, the market is speculating whether the sector is poised to bring value or is a value trap under increased clarity regarding the Trump administration’s drug pricing efforts.

READ ALSO: 13 Most Undervalued Retail Stocks to Invest In and 13 Most Oversold Large Cap Stocks So Far in 2025

Discussing this scenario, Seigerman opined that deals could be struck in the domain, which could help the sector. He added that valuations had been suppressed for a long time due to fears regarding drug pricing and tariff implementation. However, some of these fears have been uplifted with the Trump/Pfizer press conference offering a clearer path forward.

Seigerman further stated that while the dwindling uncertainty is a significant positive, it is too early to claim whether the cloud on the sector has fully lifted. It has, however, provided meaningful clarity.

With these trends in view, let’s look at the best biotech stocks with high potential.

Our Methodology

We used stock screeners to make a list of the best biotech stocks with high analyst upside potential and selected the top 13 with the highest upside. We also added the number of hedge fund holders for each stock as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of analyst upside.

Note: All data was sourced on October 6.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

14 Biotech Stocks with High Potential

14. Summit Therapeutics Inc. (NASDAQ:SMMT)

​Analyst Upside: 60.99%

Number of Hedge Fund Holders: 30

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks with high potential. In a report released on September 29, Leerink Partners maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) without assigning a price target.

In addition, Barclays also maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on September 25 with a $13 price target.

However, Asthika Goonewardene from Truist Financial maintained a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) the same day, without assigning a price target.

In addition to Asthika Goonewardene, Citi’s Yigal Nochomovitz also expressed bullish sentiments for Summit Therapeutics Inc. (NASDAQ:SMMT) in a report released on September 24, assigning the stock a Buy rating with a $35 price target.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that specializes in creating novel medications for infectious and cancerous diseases.

13. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Analyst Upside: 62.81%

Number of Hedge Fund Holders: 32

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks with high potential. On September 23, J.P. Morgan analyst Anupam Rama maintained a bullish stance on IDEAYA Biosciences, Inc. (NASDAQ:IDYA), giving the stock a Buy rating with a $74 price target.

The analyst based the rating on several promising developments associated with the company’s lead asset, darovasertib, stating that IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is anticipated to release notable updates on darovasertib in several treatment settings. This is expected to support significant value creation.

In another report released on September 22, UBS analyst David Dai reiterated a Buy rating on IDEAYA Biosciences, Inc. (NASDAQ:IDYA) and set a price target of $50.00.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) develops oncology-focused precision medicine, focusing on targeted therapeutics for patients selected using molecular diagnostics. The company’s product candidate is IDE196, a protein kinase C inhibitor that targets genetically defined cancers with GNAQ or GNA11 gene mutations.

Page 1 of 13

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!